Bruker Corporation (Nasdaq: BRKR) has announced a major innovation in its CellScape™ Precise Spatial Proteomics platform with the introduction of EpicIF™ (Enhanced photobleaching in cyclic immunofluorescence). Since its 2022 launch, the CellScape platform has set new standards in spatial proteomics by delivering high-resolution, high dynamic range (HDR) imaging, capturing the full spectrum of protein expression and detailed morphology in biological samples. With EpicIF, Bruker has enhanced this platform by expanding compatibility with commercially available fluorophore-conjugated antibodies nearly tenfold, streamlining assay development, and doubling throughput.
EpicIF uses a proprietary reagent combined with visible light to efficiently erase fluorescence signals from most fluorophores without affecting tissue integrity or epitope preservation, making the process gentler and more versatile. This enhancement is accompanied by the release of CellScape™ Navigator, an updated software with an intuitive interface for seamless experiment setup, available as an upgrade to current CellScape instruments.
“This innovation provides unprecedented flexibility in multiplexed immunofluorescence (IF) experiments,” stated Dr. Ranga Partha, SVP of Product Management and Marketing at Bruker Spatial Biology. “With EpicIF, researchers can now use a broader range of antibody conjugates, expanding applications to additional fluorescent readouts like RNA-ISH. It’s a significant advancement in spatial proteomics technology.”
Dr. Oliver Braubach, Director of R&D Assays at Bruker Spatial Biology, added, “EpicIF overcomes the limitations of traditional multiplexing by enabling the removal of signals from various organic dyes, allowing greater use of antibodies validated in other workflows and saving costs and time on optimization.”
Bruker will showcase EpicIF and the new CellScape Navigator software at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting from Nov 8-10 in Houston, Texas, booth #419.
